Salute e Benessere
MolecuLight® Applauds New CMS Local Coverage Determination (LCD) Changes for Skin Substitutes
"We are committed to supporting healthcare providers in delivering optimal wound care," said Anil Amlani, CEO at MolecuLight. "Our technology empowers clinicians to make evidence-based decisions and improve patient outcomes. We are confident that MolecuLight will play a crucial role in meeting the new LCD documentation requirements and ensuring the successful implementation of skin substitute therapies."
MolecuLight is the leader in in point-of-care fluorescence imaging. Their innovative devices empower healthcare providers to quickly and accurately detect elevated levels of bacteria in wounds, surgical sites, and other injuries. This real-time visualization of bacteria that is linked to infection empowers clinicians to make informed treatment decisions. Early and accurate detection of bacteria leads to more targeted treatment plans. By optimizing treatment plans, MolecuLight technology helps to accelerate healing and reduce the risk of complications. The multi-modal device combines bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow. For more information, please visit www.moleculight.com
Hunter Zudans , Director of Marketing, MolecuLight Inc., hzudans@moleculight.com , T. +1.484.682.7580, www.moleculight.com
View original content: https://www.prnewswire.co.uk/news-releases/moleculight-applauds-new-cms-local-coverage-determination-lcd-changes-for-skin-substitutes-302308280.html